Answers are grounded in this paper and cite their sources.
The global scale-up of HIV antiretroviral therapy (ART) has generated substantial individual and public health benefits. Viral suppression restores immune function and halts HIV transmission. Progress for children and adolescents has been more delayed than it has been for adults. As of 2022, 1·5 million children aged 1–14 years were living with HIV.1 Global estimates of viral suppression vary substantially by region, but show lower rates of viral suppression in children compared with adults. In a large cohort analysis of people who initiated ART between 2010 and 2019, adjusting for missing viral load data, 59% of those younger than 18 years had viral suppression at 3 years after the initiation of ART compared with 65% of adults.
No takes yet. Share an insight, caveat, or question.
Levison et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: